NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
New integrated testing approach provides potential to deliver earlier biomarker insights, reduce diagnostic uncertainty in complex cancer cases, and enable confident clinical decisions NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology …